Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, 24 April 2018 - Fredrik Arp has today informed Nuevolution AB's nomination committee that he has decided not to seek re-election to Nuevolution AB's board of directors at the forthcoming annual general meeting on 28 May 2018. The nomination committee has duly noted and accepted Fredrik Arp's decision. Consequently, the nomination committee proposes to reduce the number of board members from six to five at the coming annual general meeting on 28 May 2018. For practical reasons, it has been agreed that Fredrik Arp leaves the board as from today.
For more information, please contact:
Stig Løkke Pedersen, chairman in Nuevolution AB (publ)
Tel.: +45 4086 4151
Email: slp@stigloekkepedersen.dk
Information about Nuevolution AB (publ)
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution's internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.
This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact person set out above, on Tuesday 24 April 2018 at 17:30 CET.
Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com.